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Abstract
Editorial: The journey of Diagnostic Pathology in 2009, perspectives for 2010
Editorial
Diagnostic Pathology is approaching the end of its fourth
year of publication. From the beginning, Diagnostic Pathol-
ogy  has operated as an independent scientific journal,
allowing the Editor-in-Chief and Editorial Board to con-
trol the content of the journal, while the publisher pro-
vides support in these activities and regulates other
aspects including production and layout of the published
articles. The separation of these activities allows the Edito-
rial team to focus on the content and direction for the
journal, making it the best home for research in the area.
In order to make Diagnostic Pathology open access, the
journal levies an article-processing charge (APC) for each
article accepted for publication. These costs are necessary
to continue to provide the production and hosting serv-
ices as well as additional support, but they remain com-
petitive compared to other open access journals. Many
funders support open access by allowing their grants to be
used to cover the cost of publishing in open access jour-
nals [1] and more institutions are becoming BioMed Cen-
tral Members, or Supporter Members, to help their
researchers to publish open access. However, it still
remains a burden for authors, who have to both complete
a scientifically reliable and interesting publication and
pay for it. It is therefore important that authors feel that
the costs of open access publication offer a beneficial
return. How can the return be judged? What is the nature
of the return, and how does it benefit the authors?
This is primarily a question to the authors, although it is
also of importance to the journal Editors. Publishing an
article usually requires research investigation which can
last for months or years. Results and interpretation are the
fruits that are offered to colleagues, and "should be
eaten". They have to be "sweet" and to "fit into the taste"
of the potential readers. Every successful merchant knows
that the wrapping of an article is as important as the con-
tent that has to be sold successfully. The main interest of
an author in publishing scientific results is a broad access
to the corresponding scientific world, and a high reputa-
tion of the article (at home and in the scientific environ-
ment). Also of interest are the technical publication
procedures, such as fast, helpful, non-biased, and reliable
review of the article, concrete assistance in improving the
paper, and fast publication of the accepted final version.
How does Diagnostic Pathology deal with these reimburse-
ments?
Open access journals, i.e., those that can be read for free,
have a wide reader community. The readers are not lim-
ited to colleagues who are working within the same field
of the published article. They often visit a journal in
search for new ideas or even by chance, for example by
coming across relevant articles in PubMed or PubMed
Central. In addition, open access journals are embedded
in an electronic communication medium that offers sev-
eral advantages for a fast and "screening-like" visit. They
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are all provided with a fast search function, adequate links
to "related articles", easy to copy functions, or "post a
comment" message. Diagnostic Pathology offers all these
items. With a wide readership, articles are well accessed. A
total of six articles were published in November 2009, two
of which have already been read by more than 400 col-
leagues. These articles were submitted to Diagnostic Pathol-
ogy  at the end of August 2009, and published in
November 2009, i.e., the time taken from submission, to
review, revise and final publication amounts to less than
three months. The average time of acceptance was calcu-
lated as 74 days (from submission to publication).
In addition to our standard scientific quality levels it is
also our policy to encourage and support colleagues work-
ing in developing countries to publish their findings in
our journal. Taking out randomly 10 published articles in
2009, two of them were submitted from the USA, one arti-
cle each from Brazil, China, Egypt, Germany, Iran,
Poland, Spain and Turkey. These figures indicate that
Diagnostic Pathology is truely a world-wide and well known
scientific journal already in its fourth year of publication.
The scientific quality of a journal can be partly judged by
statistical methods such as the impact factor or H-index.
Although it is questionable whether these factors reflect to
the reputation of a scientific journal in its community, an
impact factor is often mandatory if scientists want to pub-
lish their results in the selected journal. The main disad-
vantage of the impact factor is its absolute value, i.e. it
depends upon the size of the journal specific scientific
community. The impact factor of pathology journals is
basically low in comparison to that of molecular biology
or biochemistry journals.
Diagnostic Pathology received its first official impact factor
in 2009, of 1.11 and is now included in the journal cita-
tion index. At a starting point the value 1.11 can be
regarded as high. It is already above that of several long
term established scientific journals in surgical pathology.
Both figures, namely the submission of articles written in
all parts of the world, the frequent access of interested col-
leagues, and the newly established citation index contrib-
ute to the journal's reputation, and can be considered as a
high quality return for the invested time and financial
input of the authors.
In summary, a successful year for Diagnostic Pathology is
coming to its end despite all constraints. A big step for-
ward in reputation and notification has been achieved,
which to our satisfaction benefits our authors.
We want to express our deep gratitude to, and we wish all
our authors, readers, reviewers, and our publication team
a Merry Christmas and a Happy and Healthy New Year.
Klaus Kayser
Editor in Chief
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